INNA-051

DRUG3 trials

Sponsors

ENA Respiratory Pty Ltd

Conditions

COVID-19 PandemicInfluenza ProphylaxisViral Respiratory IllnessesViral Respiratory Infection

Phase 2

Intranasal INNA-051 for Prevention of COVID-19 in Adults

WithdrawnNCT05118763

ENA Respiratory Pty LtdCOVID-19 Pandemic

Start: 2022-03-01End: 2022-12-31Updated: 2022-04-14

INNA-051 Influenza Challenge Study

CompletedNCT05255822

ENA Respiratory Pty LtdInfluenza Prophylaxis

Start: 2022-02-28End: 2022-08-23Updated: 2023-01-18

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

RecruitingNCT07222670

ENA Respiratory Pty LtdViral Respiratory Illnesses, Viral Respiratory Infection

Start: 2025-12-04End: 2027-04-09Target: 1100Updated: 2026-09-11